Vaxcyte PCVX
NASDAQ PCVX
$68.62 +2.26 (+3.41%)
At close: Nov 11, 2026 · 4:00 PM EST

Vaxcyte (PCVX) Preferred Stock Liabilities (2019 - 2020)

Updated

Vaxcyte's Preferred Stock Liabilities was $270.19 million in Q1 2020, up 129.3% from $117.81 million a year earlier and up 68.5% from the prior quarter.

Analysis

Vaxcyte (PCVX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends

At the end of FY2019, Preferred Stock Liabilities at Vaxcyte came in at $160.31 million, up 36.1% from FY2018.

  • In earlier years, Preferred Stock Liabilities was $117.81 million in FY2018.
  • Per Business Quant data, PCVX's Preferred Stock Liabilities in the three quarters before Q1 2020 was $160.31 million (Q4 2019), $117.81 million (Q3 2019) and $117.81 million (Q2 2019).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Vaxcyte 9.91 Bn 3.83 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 270.19 Mn
Dec 31, 2019 160.31 Mn
Sep 30, 2019 117.81 Mn
Jun 30, 2019 117.81 Mn
Mar 31, 2019 117.81 Mn
API Access

Vaxcyte Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=PCVX&period=max&api_key=YOUR_API_KEY